Dewald G W, Diez-Martin J L, Steffen S L, Jenkins R B, Stupca P J, Burgert E O
Cytogenetics Laboratory, Mayo Clinic, Rochester, Minnesota 55905.
Am J Med Genet Suppl. 1990;7:247-50. doi: 10.1002/ajmg.1320370750.
To study the role of trisomy 21 in hematologic malignancies, we investigated the hematologic disorders of 13 patients with acquired trisomy 21 and 13 individuals with Down syndrome (DS). The most common hematologic malignancy among the patients with acquired trisomy 21 involved both granulocytic and monocytic lineages. By comparison, the hematologic disorders among the DS patients were predominantly acute lymphocytic leukemia and acute megakaryocytic leukemia. Although our sample was small, our results suggest that most patients with acquired trisomy 21 have different hematologic disorders than individuals with DS. Perhaps the role of trisomy 21 in the development of hematologic malignancy is different in constitutional trisomy 21 than it is in acquired trisomy 21.
为研究21三体在血液系统恶性肿瘤中的作用，我们调查了13例获得性21三体患者和13例唐氏综合征（DS）个体的血液系统疾病。获得性21三体患者中最常见的血液系统恶性肿瘤涉及粒细胞和单核细胞系。相比之下，DS患者的血液系统疾病主要是急性淋巴细胞白血病和急性巨核细胞白血病。尽管我们的样本量较小，但我们的结果表明，大多数获得性21三体患者与DS个体的血液系统疾病不同。也许21三体在血液系统恶性肿瘤发生中的作用在先天性21三体与获得性21三体中有所不同。
